| Program | Indication | Research | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
| Efzofitimod (ATYR1923) |
Pulmonary Sarcoidosis(1) |
|
||||
| SSc-ILD(2) |
|
|||||
| Other ILD (CTD-ILD; CHP)(3) |
|
|||||
| ATYR2810 | Solid Tumors |
|
||||
| NRP2 mAbs | Inflammation |
|
||||
| AARS-1; DARS‑1(4) | Fibrosis; Inflammation; Cancer |
|
||||
| Program | Target | Phase |
|---|---|---|
| Efzofitimod (ATYR1923) | Pulmonary Sarcoidosis(1) | Phase 3 |
| SSc-ILD(2) | Phase 1 | |
| Other ILD (CTD-ILD; CHP)(3) | Phase 1 | |
| ATYR2810 | Solid Tumors | Preclinical |
| NRP2 mAbs | Inflammation | Research |
| AARS-1; DARS‑1(4) | Fibrosis; Inflammation; Cancer | Research |
(1) In partnership with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILD in Japan
(2) SSc-ILD: Scleroderma-related ILD
(3) CTD-ILD: Connective Tissue Disease-ILD; CHP: Chronic Hypersensitivity Pneumonitis
(4) The next two candidates from our tRNA synthetase platform